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Summary
Rationale Rhinoviruses (RVs) are the major triggers of asthma exacerbations. We have
shown previously that lower respiratory tract symptoms, airflow obstruction, and neutrophil-
ic airway inflammation were increased in experimental RV-induced asthma exacerbations.
Objectives We hypothesized that neutrophil-related CXC chemokines and antimicrobial
peptides are increased and related to clinical, virologic, and pathologic outcomes in
RV-induced exacerbations of asthma.
Methods Protein levels of antimicrobial peptides (SLPI, HNP 1–3, elafin, and LL-37) and
neutrophil chemokines (CXCL1/GRO-a, CXCL2/GRO-b, CXCL5/ENA-78, CXCL6/GCP-2,
CXCL7/NAP-2, and CXCL8/IL-8) were determined in bronchoalveolar lavage (BAL) fluid
of 10 asthmatics and 15 normal controls taken before, at day four during and 6 weeks
post-experimental infection.
Results BAL HNP 1–3 and Elafin were higher, CXCL7/NAP-2 was lower in asthmatics
compared with controls at day 4 (P = 0.035, P = 0.048, and P = 0.025, respectively). BAL
HNP 1–3 and CXCL8/IL-8 were increased during infection (P = 0.003 and P = 0.011,
respectively). There was a trend to increased BAL neutrophils at day 4 compared with
baseline (P = 0.076). BAL HNP 1–3 was positively correlated with BAL neutrophil num-
bers at day 4. There were no correlations between clinical parameters and HNP1–3 or IL-8
levels.
Conclusions We propose that RV infection in asthma leads to increased release of CXCL8/
IL-8, attracting neutrophils into the airways where they release HNP 1–3, which further
enhances airway neutrophilia. Strategies to inhibit CXCL8/IL-8 may be useful in treatment
of virus-induced asthma exacerbations.
Keywords airway epithelium, infection control, innate immunity, neutrophil biology,
respiratory infection
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Introduction
Patients with atopic asthma are more susceptible to
lower respiratory tract (LRT) infections and have more
severe and longer-lasting rhinovirus (RV)-induced LRT
symptoms than healthy individuals [1]. Virus infections
of the respiratory tract are frequently associated with
asthma exacerbations, with RVs as the predominant
viruses [2, 3]. RVs directly infect the lower airways [4]
resulting in increased lower respiratory symptoms,
reductions in lung function, bronchial inflammation,
and augmented airway hyperresponsiveness in asth-
matic compared with normal subjects [5].
Neutrophils are major effector cells in defence against
invading pathogens [6], and their number has been
shown to increase during RV infection in both experi-
mental models [5, 7] and naturally occurring asthma
exacerbations [8]. Antimicrobial peptides of the defensin
or cathelicidin families comprise a significant part of the
neutrophilic armamentarium against these pathogens [6].
The a-defensins (HNP 1–3) are stored in primary (azuro-
phil) neutrophil granules and constitute 30–50% of the
total protein of these organelles [9]. It has been hypothe-
sized that human rhinovirus infections should increase
levels of a-defensins in the airways [10], as they lead to
marked neutrophil infiltration and degranulation in the
airways [11] which are associated with clinical severity
of virus-induced asthma [5, 12]. However, there have
been no reports directly measuring defensins in the air-
ways of subjects with virus-induced asthma so far.
The human cathelicidin LL-37 is also released by
neutrophils upon inflammatory stimulation and has
potent bactericidal activity [13]. SLPI is another antimi-
crobial peptide produced by neutrophils (also by alveo-
lar macrophages and epithelial cells) which may play a
role in acute exacerbations of asthma. Their role in
virus-induced asthma is unknown.
Neutrophils are attracted to the airways and are acti-
vated mainly by the CXC chemokines CXCL1/GRO-a,
CXCL2/GRO-b, CXCL5/ENA-78, CXCL6/GCP-2, CXCL7/
NAP-2, and CXCL8/IL-8. Some of these (CXCL1/GRO-a,
CXCL2/GRO-b, and CXCL6/GCP-2) also have antimicro-
bial properties, while it has also been shown that elafin,
another antimicrobial peptide expressed by alveolar
macrophages and epithelial cells, is also chemotactic
for neutrophils [14].
Against this background, we hypothesized that anti-
microbial peptides are induced by RV infections in the
lower airways in vivo. To test this hypothesis and to
clarify whether this possible induction is related to air-
way neutrophilia and the expression of CXC chemokin-
es, we analysed the expression of neutrophil
antimicrobial peptides and CXC chemokines in BAL
fluid of subjects with RV-induced experimental asthma
exacerbations.
Some of the results of this study have been previ-
ously reported in abstract form [15].
Subjects, materials and methods
Subjects
The study design and the clinical and lower airway
inflammation data of the patients investigated have
been recently published in detail [5]. Briefly, two differ-
ent groups were studied. The first group consisted of
outpatients with mild atopic asthma; the second group
were healthy non-atopic individuals. Clinical and atopic
status were defined by questionnaire, skin prick testing,
serum IgE, and lung function testing including PEF,
forced expiratory volume in 1 s (FEV1), forced vital
capacity (FVC), and histamine challenge performed
according to guidelines [16]. The asthmatic group had a
concentration of histamine causing a 20% reduction in
FEV1 (PC20) < 8 mg/mL, the normal group > 8 mg/mL.
Normal subjects were taking no medication; asthmatics
inhaled short-acting b2-agonists only. None of the
asthmatic patients were given any inhaled or oral/sys-
temic steroid at any time point in the study. Subjects
were free of common cold symptoms for 6 weeks before
commencing the study. All were non-smokers.
Bronchoalveolar lavage (BAL) sampling was carried
out at baseline (2 weeks prior to virus inoculation), on
day 4 after inoculation (acute infection) and at 6 weeks
after inoculation (convalescent). Diaries were kept to
record symptoms and home lung function throughout
the study. All subjects gave written informed consent,
and the study was approved by the St Mary’s Research
Ethics Committee, St Mary’s Hospital, London, UK.
All subjects were seronegative (neutralizing antibody
titre < 1 : 2) for RV16 at screening and on repeat serol-
ogy performed on day 0 prior to inoculation, and all
subjects were negative to a PCR panel for respiratory
viruses (adenoviruses, coronaviruses 229E and OC43,
human metapneumovirus, influenza AH1/AH3/B, other
picornaviruses, parainfluenza viruses 1–3, and respira-
tory syncytial virus) and Mycoplasma and Chlamydo-
phila pneumoniae in nasal lavage at baseline [5].
Experimental RV-16 infection
Experimental infection was induced using 10 000
TCID50 RV16 [17] on day 0, with a DeVillbiss 286
atomizer as described [5]. Following inoculation, sub-
jects returned home.
Clinical assessment of RV16 infection
Clinical effects of RV16 infection were recorded using
daily diary cards enabling the calculation of a peak cold
score, a total cold score (total over the 2 week period
post-inoculation), peak and total chest scores (all
corrected for baseline symptoms and effect of bronchos-
copy), lung function testing by home spirometry (mic-
roDL, MicroMedical, Carefusion, Basingstoke, UK), and
histamine challenge were performed as described [5].
Processing of BAL
Bronchoalveolar lavage was collected in a single plastic
chamber and transferred immediately to polypropylene
tubes on ice for transport to the laboratory.
An aliquot of BAL fluid was stored unprocessed at
80°C for analysis of virus load by PCR. The remaining
BAL fluid was centrifuged, and BAL fluid was stored in
aliquots at 80°C. The BAL cell pellet was used for
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cytospin preparations for differential cell counting as
described [5].
Confirmation of RV16 infection
Rhinovirus infection was confirmed in all subjects using
PCR, by culture or by serology as described [5].
Virus load was determined in nasal lavage and the
unprocessed BAL aliquot by quantitative PCR as
described [5].
Quantification of antimicrobial peptides in BAL fluid
In BAL fluid, SLPI levels were assessed by enzyme-linked
immunosorbent assay (ELISA) using a commercially
available kit (R&D Systems, Abingdon, UK) with a sensi-
tivity of < 25 pg/mL. Samples were diluted 1 : 200. HNP
1–3 levels were measured by ELISA, using a commercially
available kit (Hycult Biotechnology, Uden, the Nether-
lands) with a sensitivity of < 156 pg/mL. Samples were
diluted 1 : 100. Elafin and human LL-37 were assessed by
ELISA kits from Cambridge Bioscience, UK, with sensitivi-
ties of < 878 pg/mL and < 0.1 ng/mL, respectively.
Chemokine analysis in BAL fluid
CXCL8/IL-8, CXCL5/ENA-78, and CXCL1/GRO-a levels
in BAL fluid were assessed by Luminex analysis (Bio-
source) on the Luminex TM 100 system with sensitivi-
ties of < 3, < 5, and < 5 pg/mL, respectively. CXCL6/
GCP-2 and CXCL7/NAP-2 were analysed by ELISA
using commercially available kits (R&D systems) with
sensitivities of < 7.8 pg/mL as well as CXCL2/GRO-b
(Antigenix America Inc, Huntington Station, NY, USA)
with a sensitivity of < 10 pg/mL.
Statistical analysis
All data were checked for normal distribution by Kol-
mogorov–Smirnov test. Normally distributed data are
presented as mean and standard deviation, whereas
non-normally distributed data are presented as median
and interquartile range.
Differences between normal and asthmatic groups
were analysed using unpaired t-tests for normally dis-
tributed data and Mann–Whitney test for non-normally
distributed data.
For discrete variables, frequencies were reported and
compared by chi-square test or Fisher’s exact test as
appropriate. The Yates correction procedure was applied
to all comparisons.
Differences during infection from baseline and con-
valescence were analysed using one-way repeated-mea-
sures ANOVA for normally distributed data. Sphericity
was assessed by Mauchly’s test. If the assumption of
sphericity was violated, degrees of freedom were cor-
rected using Greenhouse–Geisser correction for e < 0.75
or Huynh–Feldt correction for e > 0.75, respectively.
In the case of significant differences, post hoc tests
(Bonferroni correction) were performed. In case of non-
normally distributed data, Friedman’s test was used and,
if significant, post hoc tests (Wilcoxon) were performed.
Correlations for normally distributed variables were
examined using Pearson’s correlation coefficient, for
non-normally distributed variables using Spearman’s
correlation coefficient, and the respective two-tailed
significance was reported.
All significance levels were set to 5%. Data were analy-
sed and processed using GRAPHPAD PRISM 4.0 (GraphPad
Software, Inc., La Jolla, CA, USA) and SPSS 18.0 (Interna-
tional Business Machines Corp., Armonk, NY, USA).
Results
The study design, the analysis of clinical characteristics
and the clinical response to experimental viral infection
together with extensive data on the effect on the Th1/
Th2 immune response have been reported [5]. However,
here, we present a completely new analysis of data
from those 10 atopic asthmatics and 15 non-atopic nor-
mal controls that entirely completed the study.
Subjects
Baseline characteristics of all recruited subjects (11
asthmatics and 17 controls) have been reported by Mes-
sage et al. [5] recently. One asthmatic and two normal
volunteers did not continue after the baseline phase.
The clinical characteristics of the 25 subjects that com-
pleted the study and who underwent the chemokine
and anti-microbial peptide analyses reported in the
present study are summarized in Table 1.
Table 1. Clinical characteristics
Asthmatics
(n = 10)
Controls
(n = 15) Statistics* (P)
Age (years) 22.0 (2.8) 26.9 (8.9) 0.060
Gender
(F = female, M = male)
8 F/2 M 7 F/8 M 0.211
Baseline FEV1
(% predicted)
106.3 (14.0) 103.3 (13.7) 0.596
Total IgE (IU/mL) 249.3 (156.4) 26.6 (31.6) 0.001
Skin prick test
(positive/negative)
9/1 0/15 < 0.001
Data are presented as mean and (standard deviation) or as absolute
numbers (gender and skin prick test).
FEV1, forced volume in 1 s; IgE, immunoglobulin E.
*Independent-samples t-test was used for continuous and chi-square
test for categorical variables.
*Significantly different results are printed in bold.
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There were no significant differences between groups
concerning age, gender, and baseline FEV1. Features of
allergic sensitization were only expressed in the asth-
matic group.
We reported before that asthmatic patients showed
significantly higher total chest symptom score, signifi-
cantly higher maximum falls in FEV1 and PEF, and sig-
nificantly lower PC10 values at baseline, day 6, and
week 6 compared with healthy controls [5]. Lung func-
tion impairment induced by RV infection was correlated
with increased neutrophils in BAL of asthmatics sug-
gesting a role for PMNs in RV-induced exacerbations of
asthma [5]. There were no significant differences in
virus load in upper and lower airway samples between
the two groups.
Airway levels of antimicrobial peptides and neutrophil
chemoattractant chemokines
Results are summarized in Table 2.
To determine differences in mediator release between
normal and asthmatics subjects before, during, and after
RV infection, a univariate analysis between groups was
performed. This showed that BAL CXCL8/IL-8 was the
only parameter significantly different at baseline. Inter-
estingly, it was higher in the control group compared
with asthmatics (25.0 (15.2) vs. 13.4 (10.9) pg/mL,
P = 0.038, Fig. 1). Four days after infection, BAL HNP
1–3 and elafin were significantly higher in asthmatics
compared with controls (1.4 (0.7) vs. 0.7 (0.4) ng/mL,
P = 0.035, 1595.6 (791.4) vs. 823.7 (587.4–1302.1) ng/
mL, P = 0.048, respectively, Fig. 1), while BAL CXCL7/
NAP-2 was significantly higher in controls compared
with asthmatics (102.7 (45.2–213.9) vs. 45.8 (16.2),
P = 0.025, Fig. 1).
Repeated-measures multivariate analysis showed sig-
nificant differences only in asthmatic subjects. BAL
HNP 1–3 and CXCL8/IL-8 were significantly increased
at day 4 compared with baseline (Fig. 1 and Table 2).
BAL HNP 1–3 and CXCL8/IL-8 only were also signifi-
cantly increased at day 4 compared with week 6 in
asthmatic subjects (Fig. 1 and Table 2). There was a
trend to increased BAL neutrophils at day 4 compared
with baseline in asthmatic subjects (P = 0.076).
We also measured BAL IL-6, but no significant differ-
ences were observed, neither within groups at the dif-
ferent time points nor between asthmatics and controls
at any time point (data not shown).
Relationship between BAL neutrophils, soluble
mediators, virus load, and clinical parameters
BAL HNP 1–3 measured at baseline was negatively cor-
related with BAL viral load (r = 0.880, P = 0.049) in
asthmatics only (Fig. 2a). BAL viral load was available
in 5 asthmatic subjects only. Unfortunately, the other 5
samples got lost during a liquid nitrogen thawing over
Christmas/New Year and were not available for analy-
sis. BAL HNP 1–3 at baseline was correlated with BAL
CXCL8/IL-8 at baseline in asthmatics only (r = 0.753,
P = 0.031). BAL HNP 1–3 was the only parameter to be
positively correlated with relative BAL neutrophil num-
bers at day 4 post-infection (in all subjects; Fig. 2b). At
week 6, BAL HNP 1–3 was also correlated with BAL
CXCL8/IL-8 (r = 0.469, P = 0.028) in all subjects.
BAL CXCL8/IL-8 and CXCL1/GRO-a levels at day 4
post-infection were correlated with peak nasal lavage
virus load (r = 0.721, P = 0.044, and r = 0.738,
P = 0.037, respectively) in asthmatics. BAL CXCL8/IL-8
at week 6 was correlated with BAL neutrophils (in% of all
non-epithelial cells; r = 0.496, P = 0.016) in all subjects.
There were no correlations between clinical parame-
ters (FEV1 or PEF) and HNP1–3 or IL-8 levels.
Relationship between Elafin and Peak Expiratory Flow
Elafin levels at day 4 post-infection were inversely
related to maximal falls in PEF (r = 0.761, P = 0.017)
in asthmatics (Fig. 2c).
Discussion
We have investigated the effect of RV infection on the
expression of CXC chemokines and antimicrobial pep-
tides in a human experimental model of RV-induced
asthma exacerbation. We show, in accordance with
Turner et al. [18], that the neutrophil-attracting chemo-
kine CXCL8/IL-8 is significantly increased in asthmatics
compared with normal controls. BAL neutrophils tended
to be increased in asthmatics at day 4 compared with
normal controls and their number was related to HNP
1–3 levels. Significantly higher levels of the antimicro-
bial peptide HNP 1–3 were released into the airways of
asthmatic patients compared with normal controls dur-
ing infection.
Respiratory infections are the main triggers of asthma
exacerbations. Respiratory viruses are the most frequent
pathogens, and human RVs are most frequently
detected [2, 3]. It has been shown that during naturally
occurring virus-induced asthma exacerbations, neu-
trophils are recruited into the airways as part of the
immune defence [8]. The influx of neutrophils corre-
lates with symptoms and parameters of airways
obstruction such as FEV1 [19]. Accordingly, we
observed in our experimental model higher values of
BAL neutrophils at day 4 after intranasal experimental
infection. However, these changes were moderate, prob-
ably due to the small number of patients and the rather
mild severity of the induced asthma exacerbations.
Recruitment into this intensive and burdensome study
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was difficult resulting in small numbers of patients.
Moreover, also due to ethical constraints, experimental
exacerbations had to be mild in character. The results
presented are thus also consequences of these require-
ments. Symptoms and reductions in FEV1 were signifi-
cantly greater in asthmatics compared with controls as
previously reported [5]. It has been shown before that
4 days after experimental RV infection, the inflamma-
tory response of the upper airways is increased which is
associated with increased symptoms and airways
obstruction in asthmatics [20].
We report that the increase in neutrophils is associ-
ated with higher HNP 1–3 levels. This suggests that
neutrophils could be the major source of HNP 1–3. To
our knowledge, the only other cell type for which HNP
1–3 expression has been shown is cd-CD 8 cells in
blood [21]. Hence, we do not expect that there are any
other relevant cellular sources of HNP 1–3 than neu-
trophils in BAL. In favour of this is also the fact that
CXCL8/IL-8 was the only chemokine significantly
increased at day 4 in asthmatics. It has been shown that
HNP 1–3 can induce CXCL8/IL-8 [22], which may
explain to a certain degree the significantly higher lev-
els observed at day 4 [5]. Significantly higher levels of
CXCL8/IL-8 and a trend for higher CXCL1/GRO-a in
BAL at day 4 were related to high virus load measured
in nasal lavage. This may be a result of increased
induction of CXCL8/IL-8 and CXCL1/GRO-a in asthmat-
ics by RVs. It has been shown in vitro that RV infection
of human respiratory epithelial cell line significantly
increases CXCL8/IL-8 [23]. Moreover, it has been dem-
onstrated that the intramuscular injection of synthetic
HNP1 induces the transcript expression of genes encod-
ing both pro-inflammatory cytokines (IL-1beta and
TNF-alpha) and the chemokine CXCL8/IL-8. Further-
more, HNP1 showed chemotactic capacity towards leu-
cocytes [24]. These findings suggest that RV infection
induces CXCL8/IL-8, which has chemotactic activity
towards neutrophils, thereby increasing neutrophil
numbers in the airway which release HNP 1–3 which
has properties that will further enhance neutrophilia.
However, it has to be acknowledged that it is possible
that increased defensin expression could also be an epi-
phenomenon of neutrophil activation and that other
mechanisms, such as release of reactive oxygen species
or other pro-inflammatory mediators, may at least also
contribute to drive an asthma exacerbation.
All CXC chemokines investigated here are chemoattr-
actant for neutrophils, the major effector cells during
asthma exacerbation and viral airway infection. Interest-
ingly, they signal through a common receptor (CXCR2)
[25]. CXCR2 is required for RV induction of neutrophilic
airway inflammation and development of airway hyper-
responsiveness as recently demonstrated in a mouse
Fig. 1. Differences in CXC chemokines and HNP 1–3 in asthmatics (closed symbols) and normals (open symbols) at baseline (triangle), Day 4 (cir-
cle) or Week 6 (rectangle). Median values are illustrated by a horizontal bar for each group. Significant differences between groups are indicated
by horizontal lines above. Stars indicate significance levels, *P < 0.05.
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model [26]. Hence, CXCR2 could be an interesting target
for therapy in RV-induced asthma exacerbations [27].
Specific CXCR1/2 receptor antagonists are already in
clinical development [28].
Why might RV infection lead to increased expression
of human neutrophil peptides? Antimicrobial peptides
such as HNP 1–3 are important effector molecules of
neutrophils. It was suggested that a-defensins (HNP
1–3) cannot directly inactivate non-enveloped viruses
such as RVs [10]. However, recent research showed that
this is not completely true. It was shown that human
a-defensins (HD-5) can block adenovirus uncoating
[29]. Moreover, it is known that HNP 1–3 are potent
antagonists of infection by both cutaneous and mucosal
papillomavirus types by blocking virion escape from
endocytic vesicles [30]. Thus, HNP 1–3 do have direct
antiviral properties against non-enveloped viruses and
might also have direct antiviral properties against RV
infection. In addition, HNP 1–3 might have indirect
antiviral effects. They have recently been shown to
inhibit HIV-1 replication even when added 12 h post-
infection [31]. Moreover, it was demonstrated that
HNP1 can affect the ability of adenoviruses to infect
epithelial cells [32]. a-defensins have chemoattractant
properties towards both CD8+ and CD4+/CD45RA+ T
cells [33]. Increased levels of a-defensins during viral
infection could therefore recruit both CD4+ and CD8+
cells to the airways. This may enhance antiviral immu-
nity as it has been shown in a variety of murine models
that HNPs enhance antigen-specific humoral and cellular
immunity [34–36]. However, one has to bear in mind as
laid out above that increased defensin expression could
also be an epiphenomenon of airways neutrophila which
is considered to contribute to asthma exacerbations.
Elafin levels were significantly higher in asthmatics
at day 4 compared with normal controls and were 1000
times higher than those of HNP 1–3. However, elafin
levels were not significantly increased at day 4 com-
pared with baseline or convalescence. Elafin levels at
day 4 post-infection were inversely related to maximal
(a)
(b)
(c)
Fig. 2. (a) The relationship between bronchoalveolar lavage (BAL)
HNP 1–3 levels and BAL viral load at day 4 post-infection was inves-
tigated in the two subject groups. In the asthmatic group (■), there
was a significant inverse correlation between HNP 1–3 and BAL viral
load at day 4 post-infection, which was not present in the normal
group (□). (b) The relationship between BAL HNP 1–3 levels and BAL
neutrophils at day 4 post-infection was investigated in the two subject
groups. In the asthmatic group (■), there was a significant correlation
between HNP 1–3 and BAL neutrophils at day 4 post-infection. The
same relationship was observed in the normal group (□). (c) The rela-
tionship between BAL elafin levels at day 4 post-infection and peak
flow maximal fall was investigated in the two subject groups. In the
asthmatic group (■), there was a significant inverse correlation
between BAL elafin and peak flow maximal fall at day 4 post-infec-
tion, which was not present in the normal group (□).
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falls in PEF. This correlation in the absence of a signifi-
cant increase in response to RV infection (probably due
to low subject numbers) must be interpreted with cau-
tion. It might suggest that insufficient expression of this
molecule might lead to more pronounced functional
consequences of RV infection in asthmatics. However,
this has to be supported in further experimental and/or
clinical studies.
BAL CXCL7/NAP-2 levels were significantly lower in
asthmatics at day 4 compared with controls. It has been
shown in a ferret model using microarray analysis that
infection with 2009-H1N1 A/California/07 induced the
expression of multiple chemokines including CCL2/
MCP-1, CCL8/MCP-2, CCL13/MCP-4, CCL19/ELC,
CXCL7/NAP-2, and CXCL10/IP-10 [37]. A recent study
found that increased CCL5/RANTES and CXCL7/NAP-2
expression was associated with neutrophil activation in
severe stable COPD. It seems that CXCL7/NAP-2 plays a
role in the local innate immune response and that dys-
regulation of the expression of this molecule might
result in neutrophil dysfunction [38]. Clearly, this
hypothesis has to be investigated further.
This study has strengths and weaknesses. The major
strength of this study is the study design. Experimental
RV infection in humans provides an excellent model of
virus-induced asthma under controlled conditions
including application of a standard dose of a single
virus serotype and standardized clinical data collection.
Invasive sampling can be carried out under controlled
conditions repeatedly and at accurately defined time
points. However, this elaborate study design is extre-
mely labour-intensive which accounts for limitation of
number of subjects that can be included in such a
study. Thus, subject numbers have to be small. For
safety reasons, only mild asthmatics could be included
into the study. This limits the ability to study more
severe forms of asthma. Another important aspect is
that BAL sampling time points had to be limited to 3
due to the invasive character of this investigation, and
it seems possible that the time points chosen (baseline,
4 days and 6 weeks after experimental infection) do not
correspond to the peak changes in CXC chemokine and/
or AMP expression. Moreover, the analysis of soluble
markers in respiratory secretions is complex because of
dilution, modification, and degradation. Nevertheless,
we found significant differences between asthmatics
and normal controls which results from meticulous
patient characterization before inclusion. Regarding in
vitro findings and preliminary in vivo data, our results
deliver direct evidence that RV infections increase lev-
els of a-defensins in the airways. This has been
assumed as RV infections lead to marked neutrophil
infiltration and degranulation in the airways [11, 39].
This finding is of possible importance as neutrophil
degranulation is associated with clinical severity of
virus-induced asthma [12].
Conclusion
This is the first study showing increased expression of
neutrophil antimicrobial peptides in a well-defined
human model of experimental rhinoviral infection of
asthmatics. We propose that RV infection in asthma
leads to increased release of CXCL8/IL-8 thereby
attracting neutrophils into the airways where they
release HNP 1–3 which further enhances airway neutro-
philia. Further studies are warranted to better under-
stand the role and importance of these cells and
molecules in asthma exacerbations in order to identify
possible new targets for therapy.
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